Company / Capital Expenditures
Lineage Cell Therapeutics, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$522.0K
FY2025
5-year range
$64.0K / $674.0K
FY2021-FY2025
Trend
-7.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 10 years, ranging from $64,000 in FY2021 to $1M in FY2018.
Based on SEC 10-K filings.
$522,000 in FY2025 with a 5-year CAGR of +3.5%.
Declined from $674,000 to $522,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +15.4%
- 5-Year CAGR
- +3.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +3.5%, indicating consistent growth.
- In FY2025, capital expenditures decreased 7.6% year-over-year.
- Peak capital expenditures was recorded in FY2018.
- Lowest capital expenditures in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $522.0K | -7.6% |
| FY2024 | $565.0K | -16.2% |
| FY2023 | $674.0K | +98.2% |
| FY2022 | $340.0K | +431.3% |
| FY2021 | $64.0K | -85.5% |
| FY2020 | $440.0K | -20.9% |
| FY2019 | $556.0K | -58.1% |
| FY2018 | $1.3M | +6.8% |
| FY2017 | $1.2M | +156.9% |
| FY2016 | $483.0K | -78.8% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026